Potent and selective JAK1/JAK2 inhibitor; orally bioavailable
Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC50 values are 3.3 and 2.8 nM, respectively). Exhibits selectivity for JAK1/2 over Tyk2 and JAK3 (∼6-fold and >130-fold, respectively). Exhibits no significant inhibition against a commercial panel of 26 additional kinases. Inhibits JAK2V617F-mediated signaling and proliferation in Ba/F3 cells and HEL cells. Increases survival rates in a JAK2V617F-driven mouse model. Identified as targeting human host proteins that interact with SARS-CoV-2. Orally bioavailable.
Phosphate salt (Cat. No. 7048) also available.
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-125935 |
| Réf. fabricant | 18715796 |
| Nom chimique ou matériau | (3 R)-3-Cyclopentyl-3-[4-(7 H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl]propanenitrile |
| CAS | 941678-49-5 |
| Quantité | 50 mg |
| Cible | JAK Kinase Inhibitors |
| Formule moléculaire | C<sub>17</sub>H<sub>18</sub>N<sub>6</sub> |
| Poids de la formule | 2323 |
| Pureté | 98% |
